NCT05514977

Brief Summary

The investigators compare 2 different drug regimens using 2 different volumes of lidocaine with the same drug content (i.e. different concentrations) as regards efficacy of post operative analgesia following mastectomy surgery

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
82

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 25, 2022

Completed
7 days until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

August 25, 2022

Status Verified

August 1, 2022

Enrollment Period

3 months

First QC Date

May 19, 2022

Last Update Submit

August 23, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effective analgesia

    Morphine supplements needed

    First 24 hours

Secondary Outcomes (1)

  • Analgesic efficiency

    Every 2 hours in the first 24 hours

Study Arms (2)

L group

ACTIVE COMPARATOR

Patients are given 20 ml of 2 % lidocaine for ESPB

Procedure: Erector spine plane block

H group

ACTIVE COMPARATOR

Patients are given 40 ml of 1 % lidocaine for ESPB

Procedure: Erector spine plane block

Interventions

Thoracic ESPB

H groupL group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA 2 \& 3 for elective breast cancer surgery

You may not qualify if:

  • ASA \> 3
  • BMI \> 35 kg/m2
  • Contraindications to LA (coagulopathy and local infection)
  • Allergy to the drug
  • Cardiac, hepatic and renal patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo university

Cairo, Egypt

Location

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ahmed Kareem

    Kasr alainy hospital, Cairo University

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

May 19, 2022

First Posted

August 25, 2022

Study Start

September 1, 2022

Primary Completion

November 15, 2022

Study Completion

December 30, 2022

Last Updated

August 25, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations